Thursday, June 26, 2025 6/26/2025

NOVEL ADAMANTYL AROTINOIDS FOR THE PREVENTION AND TREATMENT OF PROSTATE CANCER

Award Number: R01CA133475
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2008
PERIOD OF PERFORMANCE END DATE: 07/31/2013

Group Awards By:

View Award Description

NOVEL ADAMANTYL AROTINOIDS FOR THE PREVENTION AND TREATMENT OF PROSTATE CANCER - DESCRIPTION (provided by applicant): Retinoids are vitamin A derivatives that regulate gene expression through activation of the nuclear retinoid receptors (RARs and RXRs). Due to their antiproliferative and differentiation inducing activities, retinoids have shown promise for the chemoprevention and treatment of cancer. Unfortunately, most natural and non-selective retinoid analogs cause considerable toxicity due to the activation of their nuclear receptors, which has limited their clinical use. One class of synthetic retinoid-related molecules with selective RAR activity has been described that display strong apoptotic activity in cancer cells and represent promising leads for the development of novel retinoid-like anticancer agents. The RAR3/2-selective agonist MX3350-1 and the pan- RAR antagonist MX781 are representative of this novel family of retinoid analogs, which are characterized by the presence of an adamantyl group. The mechanism of apoptosis induction by these molecules is not fully understood but several lines of evidence support that it is independent of RARs. These analogs are therefore classified as atypical retinoids and in this proposal we will refer to them as adamantyl arotinoids (AdArs). Our mechanistic studies indicate that MX3350-1 and MX781 induce apoptosis via unique mechanisms of action. Activation of the ASK-1/JNK stress pathway and caspase 9 activity are required for the induction of apoptosis by MX3350-1, whereas MX781 induces apoptosis via oxidative stress and activation of caspase 2. Moreover, MX781 inhibits IKK2 in vitro and in cell-based assays. Preliminary evaluation of a novel series of MX781 analogs demonstrates that we can use molecular modeling strategies to separate IKK2 and RAR activities. Some of the novel AdArs are stronger inhibitors of IKK2 with no RAR activity, and have improved anticancer activity; these compounds are expected to be more effective and less toxic in vivo. The main goal of this project is two fold. First, we will characterize the anticancer activity in vitro and in vivo of novel AdAr analogs with no RAR transactivation activity in prostate cancer cells. Second, we propose experiments to decipher the mechanism of action of active AdArs with an emphasis on signaling transduction pathways. The antiproliferative activity of AdArs alone or in combination with other chemotherapeutic agents will be tested in vitro against a panel of prostate cancer cell lines and normal prostate epithelial cells (aim 1). Aim 1 will also investigate the mechanism of apoptosis induction by novel AdArs. We will evaluate the chemopreventive activity of AdArs in TRAMP mice (aim 2). Aim 3 will examine the mechanism of JNK activation via oxidative stress by MX781-like AdArs. Aim 4 will explore the effect of active AdArs on the prostate cancer kinome using kinase assays on peptide microarrays. The projected mechanistic studies will enhance our understanding of AdAr action in prostate cancer cells and potentially identify novel signaling molecules that are targeted by AdArs. The latter will be essential for the future structure-based optimization of AdArs as novel anticancer agents. Moreover, the proposed in vivo studies with the novel AdAr analogs might result in novel retinoid- based therapeutic strategies for the prevention and treatment of prostate cancer. PUBLIC HEALTH RELEVANCE: Project Narrative The proposed studies are relevant to the development of novel retinoid-based anticancer drugs for the chemoprevention and treatment of prostate cancer. Retinoids have long been of interest in cancer research but limited efficacy in vivo and elevated toxicity has hampered their clinical applicability for the prevention and/or treatment of solid tumors. Evaluating the anticancer activity of novel AdAr analogs lacking RAR-mediated transactivation activity may identify compounds with improved in vivo efficacy and reduced toxicity. Furthermore, we propose mechanistic studies focused on protein kinases and signaling pathways that will impact our understanding of AdAr action in prostate cancer. This will encourage rational structure-based optimization efforts in the future to quickly advance the use of retinoid-like molecules into the clinic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $241,755 )
2012	2012	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	6	7/18/2012	NON-COMPETING CONTINUATION	$241,755
														Subtotal = $241,755

Issue Date FY: 2011 ( Subtotal = $241,755 )
2011	2011	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	5	7/20/2011	NON-COMPETING CONTINUATION	$241,755
														Subtotal = $241,755

Issue Date FY: 2010 ( Subtotal = $249,232 )
2010	2010	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	4	7/19/2010	NON-COMPETING CONTINUATION	$249,232
														Subtotal = $249,232

Issue Date FY: 2009 ( Subtotal = $239,857 )
2009	2009	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	002	3	7/13/2009	NON-COMPETING CONTINUATION	$239,857
2009	2008	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES	3550 GENERAL ATOMICS COURT	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	001	2	4/8/2009	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$112,500
2009	2008	SIDNEY KIMMEL CANCER CENTER	10905 Road To The Cure	San Diego	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	4/8/2009	NEW	-$112,500
														Subtotal = $239,857

Issue Date FY: 2008 ( Subtotal = $270,001 )
2008	2008	SIDNEY KIMMEL CANCER CENTER	10835 ALTMAN ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Cancer Treatment Research	000	1	9/15/2008	NEW	$270,001
														Subtotal = $270,001

Grand Total All Awards = $1,242,600

Top

All Categories

About

Search

Reports

Data Submission

Award Information

NOVEL ADAMANTYL AROTINOIDS FOR THE PREVENTION AND TREATMENT OF PROSTATE CANCER

Award Number: R01CA133475

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2008

PERIOD OF PERFORMANCE END DATE: 07/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer